ClinicalTrials.gg
TerminatedNCT03418571Updated Jul 30, 2019Results posted

Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection

A Phase 2 interventional study of ALX-0171 1.5 mg/kg and Placebo in Respiratory Syncytial Virus Lower Respiratory Tract Infection, sponsored by Ablynx, a Sanofi company. Terminated at 25 sites in Japan. Open to participants aged 28 Days to 2 Years. Per ClinicalTrials.gov, last updated 2019-07-30.

Sponsored by Ablynx, a Sanofi company (part of Sanofi) · Phase 2, Interventional, and Treatment

Why this study was terminated
The Sponsor decided to discontinue ALX-0171 development (due to insufficient evidence of efficacy). As a result, the ALX0171-C203 study was early terminated.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
28 Days to 2 Years
Sex
All
01

Study summary

This was a randomized, double-blind, multicenter, Phase II study (NCT03418571) designed to support the selection of an optimal dose of inhaled ALX-0171 for further clinical development, taking ethnicity into consideration.

Based on the results of the Phase IIb dose-ranging study ALX0171-C201 (RESPIRE), the Sponsor decided to discontinue ALX-0171 development in infants and to early terminate the ALX0171-C203 study.

Read the detailed description

Four dose levels were planned to be evaluated in four consecutive cohorts consisting of Japanese infants and young children aged 28 days to \<2 years with a gestational age ≥33 weeks who were hospitalized for and diagnosed with respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI):

  • Dose level 1: target dose of 1.5 mg/kg
  • Dose level 2: target dose of 3.0 mg/kg
  • Dose level 3: target dose of 6.0 mg/kg
  • Dose level 4: target dose of 9.0 mg/kg

Each cohort was planned to consist of 15 subjects enrolled and randomly assigned to receive ALX-0171 or placebo, in an allocation ratio of 4:1 (N = 12 active versus N = 3 placebo per cohort).

Due to early termination of the trial, only enrollment of Cohort 1 could be completed as planned. For Cohort 2, only 1 subject was screened but did not meet the eligibility criteria and was considered a screen failure. Therefore, data were not available for treatment groups ALX-0171 3.0 mg/kg, 6.0 mg/kg, and 9.0 mg/kg.

Of note, in line with applicable guidelines, an Independent Data Monitoring Committee (IDMC) was assigned to monitor the study. Upon completing of Cohort 1, the IDMC reviewed the available unblinded safety data and unanimously recommended to continue the study with no changes to the protocol.

02

Conditions studied

  • Respiratory Syncytial Virus Lower Respiratory Tract Infection
03

In context

Lead sponsor

Ablynx, a Sanofi company is the lead sponsor of 25 studies on the registry; none are open to participants now.

First submitted before Ablynx became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Days to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  1. Subject was a Japanese male or female infant or young child aged 28 days to \<2 years with gestational age ≥33 weeks at screening.
  2. Subject was of Japanese descent, i.e., born in Japan to Japanese parents and had Japanese maternal and paternal grandparents.
  3. Subject weighed between ≥3.0 kg and \<15.0 kg at screening.
  4. Subject was otherwise healthy, but was hospitalized for and clinically diagnosed with RSV LRTI (bronchiolitis or broncho-pneumonia), i.e., showing typical clinical signs and symptoms such as tachypnea, wheezing, cough, crackles, use of accessory muscles and/or nasal flaring.
  5. Subject had a positive RSV diagnostic test within 4 days of screening.
  6. Subject was expected to have to stay in the hospital for at least 24 hours (according to the Investigator's judgment at screening).
  7. Symptoms likely related to RSV infection (i.e., the symptoms present needed to be probably linked to the current RSV infection according to Investigator's judgment) had appeared within 4 days of screening and were not yet improving at screening and randomization.
  8. Subject fulfilled at least two of the following RSV disease severity criteria at screening and randomization:

    • Inadequate oral feeding that required feeding support (i.e., nasogastric tube or i.v. line),
    • Inadequate oxygen saturation defined as:

      • Peripheral capillary oxygen saturation (SpO2) \<95% on room air, or
      • Requiring oxygen supplementation to maintain adequate oxygen saturation with documented pre-supplementation value \<95%
    • Signs of respiratory distress defined as:

      • Respiratory rate ≥50 breaths per minute in infants up to 12 months of age, and ≥40 breaths per minute in children above 12 months, and/ or
      • Moderate or marked respiratory muscle retractions
  9. Subject had normal psychomotor development.

Others as defined in the protocol

Main exclusion criteria:

  1. Subject was known to have significant comorbidities including:

    • Genetic disorders (e.g., trisomy 21, cystic fibrosis),
    • Hemodynamically significant congenital heart disease (e.g., needing corrective therapy or inotropic support),
    • Bronchopulmonary dysplasia,
    • Any hereditary or acquired metabolic (bone) diseases,
    • Hematologic or other .
  2. Subject was known to be (HIV)-positive. If the subject was \<6 months of age, known HIV-positivity of the mother was also exclusionary.
  3. Subject was known to be .
  4. Subject had or was suspected to have an active, concurrent infection (e.g., bacterial pneumonia, urinary tract infection). Concurrent acute otitis media was not exclusionary.
  5. Subject had significant oral and/or maxillofacial malformations which would have prevented proper positioning of the face mask.
  6. Subject received invasive mechanical ventilation or non-invasive respiratory support (i.e., continuous or bilevel positive airway pressure) in the 4 weeks prior to screening.
  7. During the current admission, subject was initially hospitalized in an Intensive Care Unit (ICU) setting and/or received invasive mechanical ventilation or non-invasive respiratory support (i.e., continuous or bilevel positive airway pressure).
  8. Subject was critically ill and/or was expected to require invasive mechanical ventilation, non-invasive respiratory support (i.e., continuous or bilevel positive airway pressure), or high-flow oxygen therapy (HFOT) at levels not enabling nebulization therapy according to the Investigator's judgment. High-flow oxygen, with a maximum flow of 2 L/kg/min, was permitted under the following conditions:

    • used as Standard of Care outside ICU setting
    • could be removed for study drug administration (Note: oxygen flow at 2 L/minute could be provided through the nebulizer)
  9. Subject had received 1 or more doses of palivizumab or treatment or prophylaxis with any RSV antiviral compound (e.g., ribavirin, i.v. immunoglobulin, or any drug or vaccine for RSV [including subject's mother who had been vaccinated against RSV]) at any time prior to screening.
  10. Subject was required to continue or start systemic therapy. Subject on a maintenance therapy of inhaled corticosteroids could continue this treatment at the usual dose. Topical corticosteroids for skin disorders were permitted.
  11. Subject had clinically meaningful abnormalities on a 12-lead (ECG), which according to the Investigor's judgement did not allow participation of the subject in the study. A 12-lead ECG performed within 4 days of screening was acceptable. If not available, the 12-lead ECG could be performed at the time of screening.

Others as defined in the protocol

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    ALX-0171 1.5 mg/kg

    Biological: ALX-0171 1.5 mg/kg

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalALX-0171 1.5 mg/kg

    Drug page: Gontivimab

    ALX-0171 1.5 mg/kg was administered via a single inhalation once daily for 3 consecutive days.

  • OtherPlacebo

    Placebo was administered via a single inhalation once daily for 3 consecutive days.

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Subjects With at Least 1 Serious or Non-Serious Treatment-emergent Adverse Event (TEAE).

    Number of subjects reported with at least 1 serious or non-serious TEAEs in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.

    Time frame: From the subject's first study drug administration until completion of the subject's last visit, an average of 4 weeks

  2. Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Serious and Non-serious TEAEs.

    Number of serious and non-serious TEAEs reported in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.

    Time frame: From the subject's first study drug administration until completion of the subject's last visit, an average of 4 weeks

07

Results

Posted Jul 15, 2019
Limitations and caveats
Based on the results of the Phase IIb study ALX0171-C201 (RESPIRE), the Sponsor decided to discontinue ALX-0171 development in infants and to early terminate the ALX0171-C203 study. Therefore, no data are available for the higher dose groups.

Participant flow

Sixteen subjects were screened for Cohort 1. Of these, 15 subjects were randomized. There was 1 screen failure due to consent withdrawal. For Cohort 2, 1 subject was screened but considered a screen failure (consent withdrawal). Consent was obtained from the first subject on 1 March 2018; last subject completed the final visit on 19 October 2018

Participant flow — Overall Study
MilestoneALX-0171 1.5 mg/kgPlacebo
Started123
Completed113
Not completed10
Withdrew: Consent withdrawn by legal guardian10

Outcome measures

PrimarySafety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Subjects With at Least 1 Serious or Non-Serious Treatment-emergent Adverse Event (TEAE).

Number of subjects reported with at least 1 serious or non-serious TEAEs in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.

Time frame:
From the subject's first study drug administration until completion of the subject's last visit, an average of 4 weeks
Reported as:
Number · participants
Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Subjects With at Least 1 Serious or Non-Serious Treatment-emergent Adverse Event (TEAE).
participantsALX-0171 1.5 mg/kgPlacebo
At least one serious TEAE10
At least one non-serious TEAE81
PrimarySafety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Serious and Non-serious TEAEs.

Number of serious and non-serious TEAEs reported in the ALX-0171 1.5 mg/kg treatment group and placebo treatment group.

Time frame:
From the subject's first study drug administration until completion of the subject's last visit, an average of 4 weeks
Reported as:
Number · TEAE
Safety and Tolerability of Inhaled ALX-0171 1.5 mg/kg as Measured by the Number of Serious and Non-serious TEAEs.
TEAEALX-0171 1.5 mg/kgPlacebo
Serious TEAE20
Non-Serious TEAE181

Adverse events

Collected over From the subject's first study drug administration until the subject's study completion/discontinuation date, an average of 4 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ALX-0171 1.5 mg/kg0/12 (0%)1/12 (8.3%)8/12 (66.7%)
Placebo0/3 (0%)0/3 (0%)1/3 (33.3%)
Most frequent serious events
Most frequent serious events
EventALX-0171 1.5 mg/kgPlacebo
Pneumonia hemophilusInfections and infestations1/120/3
Pneumonia bacterialInfections and infestations1/120/3
Most frequent other events
Showing 10 of 16
Most frequent other events
EventALX-0171 1.5 mg/kgPlacebo
Hepatic function abnormalHepatobiliary disorders0/121/3
MiliariaSkin and subcutaneous tissue disorders3/120/3
Upper respiratory tract infectionInfections and infestations2/120/3
Dermatitis contactSkin and subcutaneous tissue disorders1/120/3
Dermatitis diaperSkin and subcutaneous tissue disorders1/120/3
ErythemaSkin and subcutaneous tissue disorders1/120/3
Otitis mediaInfections and infestations1/120/3
Otitis media acuteInfections and infestations1/120/3
Pneumonia bacterialInfections and infestations1/120/3
DiarrhoeaGastrointestinal disorders1/120/3

Baseline characteristics

Age, Continuous
Age, Continuous(months)ALX-0171 1.5 mg/kgPlaceboTotal
Mean7.4 ± 4.653.5 ± 3.046.6 ± 4.58
Sex: Female, Male
Sex: Female, Male(Participants)ALX-0171 1.5 mg/kgPlaceboTotal
Female527
Male718
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ALX-0171 1.5 mg/kgPlaceboTotal
American Indian or Alaska Native000
Asian12315
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

25 sites
  • Investigator Site
    Aoi-ku, Japan
  • Investigator Site
    Asahikawa, Japan
  • Investigator Site
    Fuchu-shi, Japan
  • Investigator site
    Fukuyama-shi, Japan
  • Investigator Site
    Funabashi, Japan
  • Investigator site
    Gifu, Japan
  • Investigator Site
    Isesaki, Japan
  • Investigator Site
    Kawasaki, Japan
  • Investigator Site
    Koga, Japan
  • Investigator Site
    Kurashiki, Japan
  • Investigator Site
    Kurume-shi, Japan
  • Investigator Site
    Meguro-ku, Japan
  • Investigator Site
    Minami-ku, Japan
  • Investigator site
    Nagano-shi, Japan
  • Investigator site
    Saitama-shi, Japan
  • Investigator Site
    Shimotsuke-shi, Japan
  • Investigator Site
    Takatsuki, Japan
  • Investigator Site
    Toshima-ku, Japan
  • Investigator Site
    Toyohira, Japan
  • Investigator site
    Ueda, Japan
  • Investigator site
    Wako, Japan
  • Investigator Site
    Yachiyo, Japan
  • Investigator site 1
    Yokosuka, Japan
  • Investigator site 2
    Yokosuka, Japan
  • Investigator Site
    Ōmura, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Oct 2018, 7 months.

Results were first posted in Jul 2019, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2018
First posted
Feb 1, 2018
StartActual
Mar 1, 2018
Primary completionActual
Oct 24, 2018
CompletionActual
Oct 24, 2018
Results first posted
Jul 15, 2019
Last update
Jul 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03418571
Responsible party
Sponsor
First posted
Feb 1, 2018
Start date
Mar 1, 2018
Primary completion
Oct 24, 2018
Completion
Oct 24, 2018
Results posted
Jul 15, 2019
Last update
Jul 30, 2019

Study contacts

Medical Monitor
study director · Ablynx NV

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gontivimab

Start the discussion